03 · Frontier Science
Lilly participated in a $100 million financing round for Absci, including a $40 million investment, as the company
The check went to a generative AI shop whose first antibody aims at the prolactin receptor, pattern baldness and endometriosis.
Lilly participated in a $100 million financing round for Absci, including a $40 million investment, as the company advanced an injectable antibody being studied for hair loss and endometriosis. The development sat at the intersection of antibody design, early clinical work, and a broader investment interest in injectable medicines.
The scientific point is narrower than the deal size. ABS-201 had reported Phase 1 safety data, which can show whether a first-in-human program is proceeding, but it cannot establish that the medicine works for either condition.
No approved combined product with a GLP-1 medicine was part of the evidence. The next proof is controlled efficacy data and independent review, not a financing announcement or a prediction about the injectable market.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Continue reading · Frontier SciencePeptide News / Frontier ScienceThe cancer question around GLP-1 medicines is still earlyPBS News Hour · Jun 19, 2026 · scroll to read